The Versatility of Nano-Vesicles

We are the first company to harness nature’s nano-vesicles to construct a universal influenza vaccine candidate that provides robust and durable immunity against multiple influenza strains in preclinical studies. These nano-vesicles have versatility in their applications for other diseases, including coronaviruses, cancer and allergy. Read more here in the Cornell Chronicle

By genetically engineering the surface display of the nano-vesicles , we can exquisitely target specific diseases. These designer nano-vesicles can also be used with a time-release formulation that enables long acting dosing.

Versatope's universal influenza vaccine candidate is ready for clinical studies. The Investigative New Drug (IND) application has been approved.